Search - tctmd.com

Displaying 181 - 200 of 1569

Sort: Relevancy | Date

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

November 21, 2022

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

News Daily News

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

Yael L. Maxwell

November 03, 2022

New Biomarker-Based Risk Score Performs Well in ACS

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

My Five Takeaways From TCT 2022

News Opinion Fellow Talk

My Five Takeaways From TCT 2022

Navjot Kaur Sobti, MD

October 05, 2022

October 2022 News Roundup

News Opinion CV Team Dispatch

October 2022 News Roundup

October 01, 2022

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

News Daily News

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

September 26, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

Presentation TCT 2022

TCT 22: Clopidogrel versus Aspirin in the Chronic Maintenance Period Following Percutaneous Coronary Intervention in Patients with Acute Coronary syndrome: Subgroup Analysis of the HOST-EXAM trial

Presenter: Jeehoon Kang

September 17, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Watchman FLX Gets DAPT Option Added to Label

News Daily News

Watchman FLX Gets DAPT Option Added to Label

September 06, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

TCTMD’s Top 10 Most Popular Stories for August 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2022

September 01, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Presentation ESC 2022

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Presenter: John Eikelboom

August 29, 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.